Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Last updated: 2026-10-05 07:53:19 ET
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.
The economy is expanding, yet consumer sentiment is dipping below Global Financial Crisis levels. Dr. Jason Miller breaks down the surprising disconne...
Some research suggests that GLP-1 drugs may raise the risk of a rare eye disease that causes full or partial vision loss.
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE